GCB-27b
GCB-27b is an immunostimulant that binds to CD1d. GCB-27b forms a stable and long-lasting complex with CD1d, which is presented to the TCR of NKT cells to drive immune responses. GCB-27b induces a Th1-skewed immune response in *Mus musculus*, resulting in high expression of IFN?γ with restricted IL-4 levels. GCB-27b is applicable to research related to lung metastasis of melanoma.
For research use only. We do not sell to patients.
- Formula: C52H95NO10
- Molecular Weight:894.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
GCB-27b (1-1000 nM; 72 h) potently stimulates Th1-biased cytokine production in C57BL/6 mouse splenocytes in vitro, with no observed cytotoxicity[1].
GCB-27b (100 nM; 2-24 h) forms more stable and sustained complexes with CD1d on mouse BMDCs in vitro, with enhanced surface presentation relative to αGalCer at 12, 18, and 24 h postincubation[1].
GCB-27b (24 h) potently induces Th1-biased activation of human PBMC-derived NKT cells in vitro, with a 2-fold higher frequency of IFN-γ+ cells relative to αGalCer[1].
GCB-27b has higher computed binding affinity for both human and murine CD1d than αGalCer, with a docking score of 20 for both, due to optimized hydrophobic interactions in the CD1d A' pocket[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
GCB-27b (2.33 nmol per mouse; i.p.; single dose) potently activates splenic DCs (via increased CD80 and CD86 expression) and NK cells (via elevated IFN?γ production) in C57BL/6 mice, demonstrating robust innate immune stimulation[1].
GCB-27b (0.58 nmol per mouse; i.p.; single dose) reduces B16?F10 melanoma lung metastatic nodule counts by 88% relative to αGalCer in C57BL/6 mice, driven by a potent Th1-biased cytokine response[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (n=5)[1]
-
Dosage:2.33 nmol per mouse
-
Administration:i.p.; single dose
-
Result:Induced a 10.5-fold increase in serum IFN-γ levels (measured at 24 h postinjection) relative to αGalCer.
Showed IL-4 levels (measured at 2 h postinjection) comparable to those induced by αGalCer.
Demonstrated IL-4 levels peaked at 2 h then declined, while IFN-γ levels peaked at 24 h then declined, consistent with strong Th1-biased activity.
-
Animal Model:C57BL/6 (n=3)[1]
-
Dosage:2.33 nmol per mouse
-
Administration:i.p.; single dose
-
Result:Induced significantly increased mean fluorescence intensity (MFI) of CD80 and CD86 on CD11c+ dendritic cells (DCs) relative to αGalCer.
Elevated the proportion of IFN-γ+ NK cells in the spleen to 17.6%, which is significantly higher than the proportion induced by αGalCer.
-
Animal Model:C57BL/6 (n=6; melanoma lung metastasis model)[1]
-
Dosage:0.58 nmol per mouse
-
Administration:i.p.; single dose
-
Result:Induced significantly elevated serum IFN-γ levels (measured at 24 h postinjection) relative to αGalCer, with IL-4 levels (measured at 2 h postinjection) comparable to those induced by αGalCer.
Reduced lung metastatic nodule counts by 88% relative to the αGalCer-treated group, with near-complete inhibition of lung metastasis confirmed by H&E staining.
Chemical Information
-
Molecular Weight 894.31
-
Formula C52H95NO10
-
SMILES
O[C@H]1[C@@H](CO)O[C@H](OC[C@H](NC(CC2=CC=C(OCC(CCCCCCCCC)CCCCCCCCC)C=C2)=O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)[C@H](O)[C@H]1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Tail-Vein Experimental Metastasis Xenograft
Tail-vein experimental metastasis xenograft models assess the ability of injected tumor cells to survive circulation, arrest in vascular beds, extravasate, and colonize distant organs, most commonly lung after lateral tail-vein injection; this model bypasses primary-tumor formation, local invasion, and intravasation, so the readout reflects late metastatic colonization rather than the full metastatic cascade. The main readouts are metastatic burden measured by bioluminescence imaging, gross metastatic nodules, histology, organ weight, survival, or ex vivo tumor-cell quantification; luciferase-labeled tumor cells permit longitudinal noninvasive monitoring, while histology confirms organ colonization and tissue localization.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)